Business
IDEXX Laboratories Announces Fourth Quarter and Full Year 2025 Results
WESTBROOK, Maine, February 02, 2026--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced fourth quarter and full year results.
About this update from Idexx Laboratories, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1773,"height":325,"url":"https://media.zenfs.com/en/business-wire.com/178d22941a1433593a15b19290b519a4"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/t1.UcZFENvdWScSNpMBAGQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE3NjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/178d22941a1433593a15b19290b519a4","width":960,"height":176},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/8.MD9Avi6AyGGMxbgg5r2Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00NDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/178d22941a1433593a15b19290b519a4","width":1200,"height":220}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Achieves fourth quarter revenue growth of 14% as reported and 12% organic, reflecting strong CAG Diagnostics recurring revenue, growing 12% reported and 10% organic.","length":165,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Strong organic growth benefits from IDEXX execution and commercial performance, including over 1,900 IDEXX inVue Dx™ placements, delivering a quarterly record of instrument placements and 12% year-over-year expansion of IDEXX's global premium instrument installed base.","length":273,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Delivers fourth quarter EPS of $3.08, an increase of 18% as reported and 17% on a comparable basis, supported by operating margin expansion of 150 basis points as reported and 120 basis points on a comparable basis.","length":215,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":653,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Provides initial outlook for 2026 revenue guidance range of $4,632 million - $4,720 million, reflecting growth of 7.6% - 9.6% reported and 7.0% - 9.0% organic, led by CAG Diagnostics recurring revenue growth of 8.6% - 10.6% as reported and 8.0% - 10.0% on an organic basis.","length":273,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":273,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Projects 2026 EPS of $14.29 - $14.80, an increase of 9% - 13% as reported and 10% - 14% on a comparable basis.","length":110,"tagName":"p","attribs":{}}]}],"tagName":"ul","bu...